Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  ANGIOGENESIS INHIBITORS AND STIMULATORS
A Global Strategic Business Report

This report analyzes the worldwide markets for Angiogenesis Inhibitors And Stimulators in US$ Million . The major products segments analyzed are Angiogenesis Inhibitors, and Angiogenesis Stimulators. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2003 through 2010. The report profiles 72 companies including many key and niche players worldwide such as AstraZeneca Plc, Celgene Corporation, Imclone Systems Inc, Merck KgaA, Novartis, Roche, Genentech Inc, and Chugai Pharmaceutical Co. Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1092  PAGES:    376
PRICE:    $3950  DATE:       June 2006
COMPANIES:  72  MARKET DATA TABLES:   200
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  ANGIOGENESIS INHIBITORS AND STIMULATORS (Complete Report) Pages : 376   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
II. EXECUTIVE SUMMARY56$2250
  1. Introduction.....II-14 $400  
   Angiogenesis: In the Spotlight.....II-1
Angiogenesis: A Preview.....II-1
Angiogenesis: Ushering-In a New Era.....II-1
1$100
   Angiogenesis: Fact File.....II-2
An Outline of Ongoing Angiogenesis Research.....II-2
1$100
   Milestones in Research Achieved Over the Years.....II-31$100
   Angiogenesis Makes Inroads.....II-4
Leading Anti-Angiogenic Drugs in the Global Market.....II-4
1$100
  2. Market Overview.....II-52 $300  
   Analysis by Region.....II-5
US: The Single Largest Market.....II-5
Angiogenesis Regulating Products Market in Europe.....II-5
Market for Angiogenesis Regulating Products in Rest of World.....II-5
Table 1: Global Market for Angiogenesis Regulating Products (2003-2010): Geographic Regions Ranked by CAGR – USA, Europe, and Rest of World (includes corresponding Graph/Chart).....II-5
1$300
   Selective Analysis of Angiogenesis Regulating Products.....II-6
A Focus on Key Activities During 2000-2001.....II-6
1$100
  3. Angiogenesis Repertoire.....II-78 $775  
   An Indepth Insight into Angiogenesis.....II-7
Angiogenesis: At a Glance.....II-7
Requisites for Angiogenesis.....II-7
1$100
   Table 2: Broad Categorization of Companies Pursuing Angiogenesis Research by Disease/Disorder (includes corresponding Graph/Chart).....II-8
Endogenous Regulators of Angiogenesis.....II-8
1$300
   Angiogenic Process: Sequence of Events.....II-9
Angiogenesis Process in Children.....II-9
Angiogenesis Process in Adults.....II-9
The Process of Angiogenesis in Thyroid Gland.....II-9
1$100
   Angiogenesis in Ischemic Heart.....II-10
Factors Influencing Ischemic Angiogenesis.....II-10
Angiogenesis and CAD.....II-10
1$100
   Angiogenesis in Wound Healing.....II-11
Factors Stimulating Wound Angiogenesis.....II-11
Factors Impairing Wound Angiogenesis.....II-11
Angiogenic Therapy Vs Conventional Therapy.....II-11
Types of Angiogensesis.....II-11
Excessive Angiogenesis.....II-11
Insufficient Angiogenesis.....II-11
1$100
   Tumor Angiogenesis.....II-12
Sequence of Actions.....II-12
Angiogenesis and Tumor Progression.....II-12
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on Tumor
  Angiogenesis.....II-12
1$100
   Role of Angiogenesis in Skin Diseases.....II-13
Current State of Select Drugs & Their Targeted Application.....II-13
Analysis of Developmental Activities Between Decades.....II-13
1$100
   Role of Enzymes and Inflammatory Cells in Angiogenesis.....II-14
Angiogenic Imbalance Augments Retinal Neovascularization.....II-14
Oncogenes & VE –cadherin – A Facilitating Role.....II-14
1$100
  4. Angiogenesis Inhibitors.....II-1525 $1250  
   Table 3: Global Market for Angiogenesis Inhibitors (2003-2010): Geographic Regions Ranked by CAGR – USA, Europe, and Rest of World (includes corresponding Graph/Chart).....II-15
Angiogenic Inhibitors: Basic Framework.....II-15
Natural Inhibitors.....II-15
Thrombospondin.....II-15
Interferon.....II-15
1$300
   Cryptic Inhibitors.....II-16
Other Natural Inhibitors.....II-16
Natural Sources for Anti-Angiogenic Action.....II-16
Potential Anti-Angiogenic Drugs of Natural Origin.....II-16
Angiogenic Inhibitors: On the Verge of Attaining Superior Clinical Efficacy.....II-16
1$100
   Endogenous vs Synthetic Agents.....II-17
Angiogenesis Inhibitors: Classification Based on Source of Origin.....II-17
Anti-Angiogenic Molecules: Classification Based on Mode of Action.....II-17
1$100
   Broad Overview of Anti-Angiogenic Therapies.....II-18
Pre-Requisites for Any Drug to be an Angiogenic Inhibitor.....II-18
Specific Therapeutic Strategies of Anti- Angiogenesis Agents.....II-18
1$100
   Inhibiting Angiogenesis In Vivo.....II-19
Antiangiogenic Tumor Therapy.....II-19
Antivascular Therapy: Adding a New Dimension.....II-19
Antagonists to Angiogenesis.....II-19
Endostatin.....II-19
Interferon a.....II-19
1$100
   Pigment Endothelium-Derived Factor (PEDF).....II-20
Angiostatin.....II-20
SP5.2.....II-20
PTK787/ZK 222584.....II-20
Rofecoxib.....II-20
Celecoxib.....II-20
PI-88.....II-20
1$100
   Interferon –alpha2a (IFN-alpha2a).....II-21
SU6668.....II-21
Angiozyme.....II-21
Suramin.....II-21
Thrombospondin –1.....II-21
Platelet Factor 4.....II-21
Tissue Inhibitors of Metalloproteinase.....II-21
1$100
   Genistein.....II-22
Other Angiogenesis Inhibitors.....II-22
Few Recent Developments.....II-22
Avastin Together with Vascular Disrupting Agent, Combretastatin A4 Phosphate (CA4P)
  Exhibits Improved Antiangiogenic activity.....II-22
Rigel Pharmaceuticals, Inc. Discovers Role of Axl Kinase in Tumor Formation.....II-22
1$100
   Role of Platelets in Regulating Angiogenesis.....II-23
Milk Ceramide Acts as an Anti-Angiogenic Agent.....II-23
Alchemia Develops a Line of Somatostatin Agonists.....II-23
EntreMed, Inc. in Collaboration with Affymax Brought to Light Unique Synthetic
  Peptides With Improved Antiangiogenic Activity.....II-23
1$100
   Novel Angiogenesis Inhibitors- On the Horizon.....II-24
PTK 787.....II-24
Sorafenib.....II-24
Sutent.....II-24
Projected Launch Timing of Leading Angiogenesis Inhibitors To Treat Different
  Variants Cancer.....II-24
1$100
   Development Status of Select Angiogenesis Inhibitors.....II-251$100
   Tumstatin Peptides Show Promising Role.....II-26
Canstatin: Their Influence on Prostrate Cancer.....II-26
LCE Found to Exhibit Inhibitory Action.....II-26
1$100
   Strategies Commonly Deployed for Designing Anti-Angiogenesis Agents.....II-27
Current State of Angiogenesis/EGFR Targeting Agents.....II-27
Product Status of Integrin Antagonists.....II-27
1$100
   Bi-Functional Modulators.....II-28
Activities in Angiogenesis.....II-28
Angiogenesis Inhibitors Market: Companies Classified Based on Pharmacologic
  Activity.....II-28
Anti-Angiogenic Agents.....II-28
ERBITUX™ (Cetuximab).....II-28
1$100
   Glivec / Gleevec (imatinib mesylate).....II-29
Herceptin (Tractuzumab).....II-29
Iressa (gefitinib).....II-29
Thalomid® (thalidomide).....II-29
Table 4: Thalomid – Percentage Breakdown Based on Relative Oncology Application (includes corresponding Graph/Chart).....II-29
1$300
   Vioxx and Celebrex.....II-30
Avastin.....II-30
Cilengitide.....II-30
1$100
   Angiobalans.....II-31
Neovastat.....II-31
Anti-Gastrin Immunogen.....II-31
Imiquimod.....II-31
1$100
   Overview of Select Angiogenesis Inhibitors Categorized by Type.....II-321$100
   MMPs – Exhibiting Dual Role.....II-331$100
   Applications of Angiogenic Inhibitors vis-à-vis Disease Perspective.....II-34
Cancer.....II-34
Diabetic Retinopathy.....II-34
Female Reproductive Cycle.....II-34
Psoriasis.....II-34
Inflammatory Diseases.....II-34
1$100
   Table 5: Classification of Anti-Angiogenic Compounds Based on Most Commonly Targeted Indication (includes corresponding Graph/Chart).....II-35
Age-Related Macular Degeneration.....II-35
1$300
   Select Angiogenic Inhibitors for Age Related Macular Degeneration.....II-36
Angiogenesis Inhibitors Vs Standard Chemotherapy.....II-36
1$100
   Comparison Between Cytostatic Antiangiogenesis and Cytotoxic Chemotherapy.....II-37
Proteoglycan Mixture: Therapeutic Powerhouse.....II-37
Features of VascuStatin.....II-37
Angiogenesis Inhibition Versus Cytotoxic Therapy.....II-37
1$100
   Relationship Between Copper and Angiogenesis.....II-38
Anti-Angiogenesis Action of Pencillamine.....II-38
Outline of Steps Involved in Drug Discovery for Angiogenesis.....II-38
Drug Delivery: Their Influence on Therapeutics.....II-38
2$100
  5. Promoters of Angiogenesis/Angiogenesis Stimulators.....II-404 $400  
   Angiogenesis Stimulators.....II-40
Growth Factors.....II-40
Angiogenic Stimulators in the Market.....II-40
Table 6: Global Market for Angiogenesis Stimulators (2003-2010): Geographic Regions Ranked by CAGR – Europe, USA, and Rest of World (includes corresponding Graph/Chart).....II-40
Stimulators Exhibiting Profound Influence on Angiogenesis.....II-40
Vascular Endothelial Growth Factor (VEGF).....II-40
1$300
   VEGF and Their Influence on Diabetes and Diabetic Retinopathy.....II-41
Development State of VEGF Inhibitors.....II-41
Fibroblast Growth Factors (FGFs).....II-41
1$100
   Basic Fibroblast Growth Factor (bFGF).....II-42
Placental Growth Factor (PlGF).....II-42
Recombinant a4 Fragment.....II-42
Hepatocyte Growth Factor/ Scatter Factor (HGF/SF).....II-42
Angiogenin.....II-42
Platelet Derived Endothelial Cell Growth Factor.....II-42
1$100
   Applications of Angiogenic Stimulators vis-à-vis Disease Perspective.....II-43
Cardiac Diseases.....II-43
Wound Healing and Burns.....II-43
Critical Limb Ischaemia.....II-43
Status of Angiogenic Inducers.....II-43
State of Development of Protein and Gene Therapies.....II-43
1$100
  6. Recent Industry Activity.....II-448 $675  
   Schering AG and Novartis Signs a Agreement to Commercialize Angiogenesis Inhibitor,
  PTK787.....II-44
Bausch & Lomb Signs an Option Agreement with PTC Therapeutics.....II-44
Bausch & Lomb Receives License from Cephalon, Inc.....II-44
Pharmacopeia Signs a Licensing Agreement with Allergan.....II-44
1$100
   Xantos Biomedicine and Cryptome Enters into Licensing Agreement.....II-45
EntreMed, Inc. Receives US Patent.....II-45
Compound Therapeutics Acquires Strategic Assets of Phylos.....II-45
Sanofi Announces Plans to Acquire Aventis.....II-45
ThromboGenics Enters into Collaborative Agreement with Geymonat S.p.A......II-45
AngioGenex Signs Development and Marketing Agreement with BioCheck.....II-45
1$100
   Progen Industries Limited Bags Orphan Drug Status from US FDA.....II-46
Regeneron Pharmaceuticals Initiates Phase I Clinical Trials in Cancer.....II-46
Roche Group to Undertake Expansion Program.....II-46
Genentech Bags US FDA Approval for Avastin.....II-46
Regeneron and Aventis Initiate a Clinical Development Program.....II-46
EntreMed Signs Licensing Agreement with Celgene Corporation.....II-46
1$100
   Progen Industries Limited Receives EU Patent.....II-47
Phylonix Pharmaceuticals Bags Phase II SBIR Grant.....II-47
2002.....II-47
1$100
   2001.....II-48
4$400
  7. Focus on Select Global Players.....II-522 $200  
   AstraZeneca Plc. (UK).....II-52
Celgene Corporation (USA).....II-52
Imclone Systems Inc. (USA).....II-52
Merck KgaA (Germany).....II-52
1$100
   Novartis (Switzerland).....II-53
Roche (Switzerland).....II-53
Genentech Inc. (USA).....II-53
Chugai Pharmaceutical Co. Ltd. (Japan).....II-53
1$100
  8. Global Market Perspective.....II-54   
   Table 7: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-54

Table 8: World 7-Year Perspective for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2005 and 2010 (includes corresponding Graph/Chart).....II-54
1$300
   Table 9: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-55

Table 10: World 7-Year Perspective for Angiogenesis Inhibitors by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2005 and 2010 (includes corresponding Graph/Chart).....II-55
1$300
   Table 11: World Recent Past, Current & Future Analysis for Angiogenesis Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-56

Table 12: World 7-Year Perspective for Angiogenesis Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2005 and 2010 (includes corresponding Graph/Chart).....II-56
1$300
III. MARKET32$1950
  1. The United States.....III-122 $1350  
   A. Market Analysis.....III-1
US Spearheading the Angiogenesis Market.....III-1
Market Snapshots.....III-1
1$75
   The Rising Concern.....III-2
Cancer.....III-2
Cancer Statistics in US.....III-2
Phases of Cancer Trials.....III-2
1$75
   A Picture of Colon Cancer in the US.....III-3
Angiogenesis Inhibitors Under Pipeline to Treat Colorectal Cancer (2004).....III-3
Pancreatic Cancer.....III-3
Angiogenesis Inhibitors Under Pipeline that Targets Pancreatic Cancer.....III-3
1$75
   Vital Statistics.....III-4
Table 13: New Cancer Cases Among Men in the US in 2005 & 2006 (In Number) (includes corresponding Graph/Chart).....III-4
1$150
   Table 14: Cancer Mortality Statistics Among Men in US in 2005 & 2006 (In Number) (includes corresponding Graph/Chart).....III-51$150
   Table 15: New Cancer Cases Among Women in the US in 2005 & 2006 (In Number) (includes corresponding Graph/Chart).....III-61$150
   Table 16: Cancer Mortality Statistics Among Women in US in 2005 & 2006 (In Number) (includes corresponding Graph/Chart).....III-71$150
   Comparative Analysis for Select Late-Stage Angiogenesis Inhibitors: Treating Renal
  Cell Carcinoma (RCC).....III-8
Table 17: Percentage Breakdown of Select Emerging Angiogeneic Inhibitors: Targeting Front Line Renal Cell Carcinoma (includes corresponding Graph/Chart).....III-8
1$150
   Table 18: Percentage Breakdown of Select Emerging Angiogeneic Inhibitors Targeting 2nd Line Renal Cell Carcinoma (includes corresponding Graph/Chart).....III-9
Anti-Angiogenesis Therapeutics Under Pipeline that Treat Breast Cancer
  (2003).....III-9
AMD and DME Incidence in the US.....III-9
Rheumatoid Arthritis: Another Emerging Threat.....III-9
1$150
   Diabetic Retinopathy.....III-10
Angiogenic Inhibitors.....III-10
Leading Anti-Angiogenesis Drugs.....III-10
Angiogenesis Stimulators.....III-10
Coronary Artery Disease (CAD).....III-10
1$75
   Peripheral Arterial Disease.....III-11
Market Influencers.....III-11
Types of Drug Approvals.....III-11
New Drug Approval (NDA).....III-11
Orphan Drug Act.....III-11
Benefits Derived on Successful Grant of Orphan Drug Status.....III-11
Angiogenesis Foundation.....III-11
Key Role of the Foundation in Angiogenesis.....III-11
1$75
   Strategic Corporate Developments.....III-125$250
   Key & Emerging Players in the US.....III-17
Abbott Laboratories.....III-17
1$75
   Abgenix Inc......III-18
Angstrom Pharmaceuticals Inc......III-18
BioStratum Inc......III-18
Callisto Pharmaceuticals, Inc......III-18
Celgene Corporation.....III-18
1$75
   Cephalon Inc......III-19
Collateral Therapeutics, Inc......III-19
Compound Therapeutics Inc......III-19
Eisai Inc......III-19
EntreMed Inc......III-19
1$75
   Eyetech Pharmaceuticals, Inc......III-20
Genaera Corporation.....III-20
Genentech Inc......III-20
GenVec Inc......III-20
Genzyme Corp......III-20
1$75
   Imclone Systems Inc......III-21
Intradigm.....III-21
Pfizer Inc......III-21
Regeneron Pharmaceuticals.....III-21
1$75
   B. Market Analytics.....III-22
Table 19: US Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-22

Table 20: US 7-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2005 and 2010.....III-22
1$150
  2. Europe.....III-236 $450  
   A. Market Analysis.....III-23
Facet of Angiogenesis in the European Market.....III-23
Angiogenesis Market in the Recent Years.....III-23
1$75
   Table 21: Mortality Statistics of Select Cancer Types in Europe in 2002 (includes corresponding Graph/Chart).....III-24
Strategic Corporate Developments.....III-24
2$250
   Key & Emerging Players in Europe.....III-26
AstraZeneca Plc. (UK).....III-26
Celltech Group Plc. (UK).....III-26
1$75
   Merck KgaA (Germany).....III-27
Novartis (Switzerland).....III-27
Roche (Switzerland).....III-27
ThromboGenics Limited (Ireland).....III-27
1$75
   B. Market Analytics.....III-28
Table 22: European Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-28

Table 23: European 7-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2005 and 2010.....III-28
1$150
  3. Rest of World.....III-294 $325  
   A. Market Analysis.....III-29
Angiogenesis Market – Making a Positive Move.....III-29
Japanese Market.....III-29
Quest for New Opportunities.....III-29
Table 24: Mortality Statistics of Select Cancer Types in Japan During 2002 (includes corresponding Graph/Chart).....III-29
1$150
   Strategic Corporate Developments.....III-301$75
   Emerging Players in Rest of World.....III-31
AEterna Zentaris Inc. (Canada).....III-31
Chugai Pharmaceutical Co. Ltd. (Japan).....III-31
Progen Industries (Australia).....III-31
1$75
   B. Market Analytics.....III-32
Table 25: Rest of World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....III-32

Table 26: Rest of World 7-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2005 and 2010 .....III-32
1$150
IV. COMPETITIVE LANDSCAPE274$995
  
Total Companies Profiled: 72 (including Divisions/Subsidiaries - 84 )

Region/Country                   Players

The United States                  54
Canada                              2
Japan                               2
Europe                             19
     France                         2
     Germany                        4
     The United Kingdom             3
     Italy                          3
     Rest of Europe                 7
Asia-Pacific (Excluding Japan)      7
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2008, Global Industry Analysts, Inc., USA.